Table 2.
Treatment-related adverse events (N = 36)
| Adverse eventa | Any Grade | Grade 1 | Grade 2 |
|---|---|---|---|
| All | 26 (72%) | 25 (69%) | 9 (25%) |
| Fatigue | 13 (36%) | 12 (33%) | 1 (3%) |
| Rash | 13 (36%) | 13 (36%) | 0 |
| Arthralgia | 8 (22%) | 3 (8%) | 5 (14%) |
| Myalgia | 6 (17%) | 4 (11%) | 2 (6%) |
| Decreased appetite | 5 (14%) | 5 (14%) | 0 |
| Hypothyroidism | 5 (14%) | 0 | 5 (14%) |
| Pruritus | 3 (8%) | 3 (8%) | 0 |
| Dysgeusia | 2 (6%) | 2 (6%) | 0 |
| Insomnia | 2 (6%) | 2 (6%) | 0 |
| Xerostomia | 2 (6%) | 2 (6%) | 0 |
| Nausea | 1 (3%) | 1 (3%) | 0 |
| Cough | 1 (3%) | 0 | 1 (3%) |
| Diarrhea | 1 (3%) | 1 (3%) | 0 |
| Dry skin | 1 (3%) | 1 (3%) | 0 |
| Stomatitis | 1 (3%) | 0 | 1 (3%) |
| Hyperthyroidism | 1 (3%) | 1 (3%) | 0 |
| Neutropenia | 1 (3%) | 1 (3%) | 0 |
| White blood cell count decreased | 1 (3%) | 1 (3%) | 0 |
Data are n (%). The table shows treatment-related adverse events that occurred in any enrolled patients. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
aNo grade 3–5 adverse events occurred in all 36 included patients